Latest news
-
Copley launches new BAC 200iX breath actuation controller
Copley Scientific has announced the launch of its new BAC 200iX breath actuation controller for use in aerodynamic particle size distribution and delivered dose uniformity testing of MDIs, DPIs, SMIs, and nebulizers. The announcement notes… [Read more . . .]
-
EMA grants orphan drug designation to Enterprise Therapeutics’ ETD001 inhaled ENaC blocker for CF
Enterprise Therapeutics announced that the EMA has granted orphan drug designation to the company’s ETD001 inhaled epithelial sodium channel for the treatment of cystic fibrosis. Earlier this year, the company announced that a Phase 2… [Read more . . .]
-
MVIC and Upperton announce partnership to offer OINDP development services through to clinical trial supply
The Medicon Valley Inhalation Consortium (MVIC) and Upperton Pharma Solutions have announced a collaboration “designed to provide pharmaceutical and biotech companies with a seamless, end-to-end solution spanning early discovery, formulation development, preclinical support, and clinical… [Read more . . .]
-
Aptar facility in New Jersey gets controlled substances registration
Aptar Pharma has announced that its facility in Boonton, NJ, USA is now authorized to handle, store, manufacture and test DEA Schedule II and Schedule III controlled substances, adding to existing capacities for handling high potency… [Read more . . .]
-
Orexo to assess suitability of its AmorphOx technology for dry powder nasal formulations of SVF’s LNP-encapsulated mRNA vaccines
Orexo has announced that it will evaluate the ability of its AmorphOX dry powder platform to create stable formulations of SVF’s LNP-encapsulated mRNA vaccines for nasal delivery. Orexo has its own pipeline of intranasal dry… [Read more . . .]
Other recent news
-
Hovione announces that Guy Villax will take over as Chairman of the Board
-
LionBio to develop intranasal GLP-1
-
Phillips Medisize acquires remaining portion of former Vectura site
-
Ethris says Phase 2a trial of ETH47 intranasal antiviral in asthma patients demonstrated safety and antiviral activity
-
Abera gets approval for Phase 1 trial of its Ab-01.12 intranasal pneumococcal vaccine

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK









